Catch up on when we welcomed back our donors and supporters to our first in person event in over two years to the Melbourne Musuem on 3 November 2022.
Vision is one of the most precious gifts we have. It was not too long ago many conditions – including age-related macular degeneration (AMD) and Inherited Retinal Diseases (IRD) – were considered completely untreatable. But now, thanks to years of hard work to fully understand the mechanisms behind these conditions, we are closer than ever before to many new and improved therapies.
Speaking at this event:
- CERA Managing Director and Head of Glaucoma Research Professor Keith Martin
- Head of Macular Research Professor Robyn Guymer AM
- Head of Clinical Trials Associate Professor Lyndell Lim
- Head of Ophthalmic Neuroscience Associate Professor Peter van Wijngaarden
Professor Robyn Guymer AM is a Deputy Director of CERA, the Head of Macular Research at CERA, and Professor of Ophthalmology at Melbourne University. She is also a senior retinal specialist at the Royal Victorian Eye and Ear Hospital and a clinician scientist who leads a team of researchers primarily investigating age-related macular degeneration (AMD).
Associate Professor Lyndell Lim is the Head of Clinical Trials Research at CERA and Associate Professor of Ophthalmology at the University of Melbourne. Lyndell’s main research interests include clinical studies in the field of uveitis and ocular immunology, and diabetic retinopathy.
Associate Professor Peter van Wijngaarden is Deputy Director of the Centre for Eye Research Australia and Associate Professor of Ophthalmology at the University of Melbourne. Peter is also an ophthalmologist and medical scientist with research interests in diabetic retinopathy, Alzheimer’s disease and retinal imaging biomarker discovery.
